Illumina

NIH awards $14.5M to research groups studying DNA sequencing techniques

Tuesday, August 5, 2014 09:00 AM

A number of micro-sized technologies—such as nanopores and microfluidics—are among the approaches researchers will use to develop high-quality, low-cost DNA sequencing technology through new grants from the NIH. The grants, which total approximately $14.5 million to eight research teams over two to four years as funds become available, are the last to be awarded by the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute (NHGRI), a part of NIH.

More... »

WIRB Copernicus Group

U.K. genomics projects granted $505M

Friday, August 1, 2014 01:41 PM

Genomics England’s 100,000 Genomes Project has received a package of investment worth more than $505 million. The four year project focuses on new research to decode 100,000 human genomes—a patient’s personal DNA code.

More... »


Illumina launches the Illumina Accelerator Program

Friday, February 14, 2014 01:52 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has launched the Illumina Accelerator Program, the world's first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. Its goal is to speed the time to market and lower the barriers to entry for entrepreneurs, startups and early stage companies working on scientifically and commercially promising next-generation sequencing (NGS) applications.

More... »

Sony, M3, Illumina to launch new genome company in Japan

Monday, January 27, 2014 01:24 PM

Sony, M3 and Illumina have formed a collaboration to launch a "genome information platform" in Japan. Sony and M3 will establish a new company, with Illumina as a minority investor, by the end of February.

More... »

Amgen, Illumina to develop oncology companion diagnostic test

Friday, January 17, 2014 11:42 AM

Illumina, a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has entered into an agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), a fully human anti-EGFR monoclonal antibody therapeutic for the treatment of metastatic colorectal cancer approved in the U.S. and E.U.

More... »

Illumina to acquire NextBio

Monday, October 28, 2013 02:20 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function based in San Diego, will acquire Santa Clara-based NextBio, a provider of clinical and genomic informatics.

More... »

University of Cambridge, Genomics England, Illumina collaborate

Monday, October 21, 2013 01:36 PM

University of Cambridge, Genomics England and Illumina have announced the launch of a three-year project to sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project is a pilot for Genomics England, which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the U.K. National Health Service (NHS).

More... »

Almac launches TruSight tumor profiling next-generation sequencing service

Wednesday, September 11, 2013 01:37 PM

Almac has launched a tumor profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor panel as part of their biomarker discovery, development and delivery solutions.

More... »

Pathogenica, Illumina in co-marketing deal

Wednesday, July 17, 2013 12:30 PM

Pathogenica, a provider of medical diagnostic sequencing services and products, and Illumina have agreed to co-market in the Asia Pacific region a new version of Pathogenica's HAI BioDetection kit compatible with Illumina's MiSeq benchtop sequencing system. The combined solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.

More... »

Partners HealthCare, Illumina announce founding members of GeneInsight Network

Monday, January 14, 2013 02:49 PM

Partners HealthCare, a Boston-based integrated health system, and Illumina, a developer, manufacturer and marketer of life science tools and integrated systems, announced the GeneInsight-Illumina Founding Network Members, including the ARUP Laboratories, Mount Sinai Genetic Testing Laboratory, New York Genome Center (NYGC), Partners HealthCare and Illumina.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs